These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20461036)

  • 1. Characterization and analysis of human chordoma cell lines.
    Yang C; Hornicek FJ; Wood KB; Schwab JH; Choy E; Iafrate J; Rosenberg A; Nielsen GP; Xavier RJ; Mankin H; Duan Z
    Spine (Phila Pa 1976); 2010 Jun; 35(13):1257-64. PubMed ID: 20461036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines.
    Karikari IO; Gilchrist CL; Jing L; Alcorta DA; Chen J; Richardson WJ; Gabr MA; Bell RD; Kelley MJ; Bagley CA; Setton LA
    J Neurosurg Spine; 2014 Sep; 21(3):386-93. PubMed ID: 24905390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and characterization of a novel chordoma cell line: CH22.
    Liu X; Nielsen GP; Rosenberg AE; Waterman PR; Yang W; Choy E; Sassi S; Yang S; Harmon DC; Yang C; Schwab JH; Kobayashi E; Mankin HJ; Xavier R; Weissleder R; Duan Z; Hornicek FJ
    J Orthop Res; 2012 Oct; 30(10):1666-73. PubMed ID: 22504929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.
    Duan Z; Choy E; Harmon D; Yang C; Ryu K; Schwab J; Mankin H; Hornicek FJ
    PLoS One; 2009 Sep; 4(9):e6967. PubMed ID: 19742314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of chemotherapeutic agents on differentiated chordoma cells.
    Bayrak OF; Aydemir E; Gulluoglu S; Sahin F; Sevli S; Yalvac ME; Acar H; Ozen M
    J Neurosurg Spine; 2011 Dec; 15(6):620-4. PubMed ID: 21905773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
    Moneo V; Serelde BG; Fominaya J; Leal JF; Blanco-Aparicio C; Romero L; Sánchez-Beato M; Cigudosa JC; Tercero JC; Piris MA; Jimeno J; Carnero A
    J Cell Biochem; 2007 Feb; 100(2):339-48. PubMed ID: 16888811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin is a promising antitumour agent for synovial sarcoma.
    Yasui H; Imura Y; Outani H; Hamada K; Nakai T; Yamada S; Takenaka S; Sasagawa S; Araki N; Itoh K; Myoui A; Yoshikawa H; Naka N
    J Chemother; 2016 Oct; 28(5):417-24. PubMed ID: 27077926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.
    Duan Z; Choy E; Jimeno JM; Cuevas Cdel M; Mankin HJ; Hornicek FJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1121-9. PubMed ID: 18828019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and characterization of a chordoma cell line from the tissue of a patient with dedifferentiated-type chordoma.
    Kim JY; Lee J; Koh JS; Park MJ; Chang UK
    J Neurosurg Spine; 2016 Nov; 25(5):626-635. PubMed ID: 27314550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma.
    Yang C; Hornicek FJ; Wood KB; Schwab JH; Choy E; Mankin H; Duan Z
    Spine (Phila Pa 1976); 2010 Aug; 35(18):1668-75. PubMed ID: 20386502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells.
    Acikgoz E; Guven U; Duzagac F; Uslu R; Kara M; Soner BC; Oktem G
    PLoS One; 2015; 10(10):e0141090. PubMed ID: 26485709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel target for treatment of chordoma: signal transducers and activators of transcription 3.
    Yang C; Schwab JH; Schoenfeld AJ; Hornicek FJ; Wood KB; Nielsen GP; Choy E; Mankin H; Duan Z
    Mol Cancer Ther; 2009 Sep; 8(9):2597-605. PubMed ID: 19723879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of repurposed small molecule drugs for chordoma therapy.
    Xia M; Huang R; Sakamuru S; Alcorta D; Cho MH; Lee DH; Park DM; Kelley MJ; Sommer J; Austin CP
    Cancer Biol Ther; 2013 Jul; 14(7):638-47. PubMed ID: 23792643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers.
    Stevens EV; Nishizuka S; Antony S; Reimers M; Varma S; Young L; Munson PJ; Weinstein JN; Kohn EC; Pommier Y
    Mol Cancer Ther; 2008 Jan; 7(1):10-8. PubMed ID: 18187810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs.
    Kato TA; Tsuda A; Uesaka M; Fujimori A; Kamada T; Tsujii H; Okayasu R
    Radiat Oncol; 2011 Sep; 6():116. PubMed ID: 21914223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
    Mabuchi S; Hisamatsu T; Kawase C; Hayashi M; Sawada K; Mimura K; Takahashi K; Takahashi T; Kurachi H; Kimura T
    Clin Cancer Res; 2011 Jul; 17(13):4462-73. PubMed ID: 21622721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and Therapeutic Potential of SOX9 in Chordoma.
    Chen H; Garbutt CC; Spentzos D; Choy E; Hornicek FJ; Duan Z
    Clin Cancer Res; 2017 Sep; 23(17):5176-5186. PubMed ID: 28606919
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
    Romano M; Frapolli R; Zangarini M; Bello E; Porcu L; Galmarini CM; García-Fernández LF; Cuevas C; Allavena P; Erba E; D'Incalci M
    Int J Cancer; 2013 Nov; 133(9):2024-33. PubMed ID: 23588839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing.
    Voissiere A; Jouberton E; Maubert E; Degoul F; Peyrode C; Chezal JM; Miot-Noirault É
    PLoS One; 2017; 12(7):e0181340. PubMed ID: 28704566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EP300 through upregulating the expression of vimentin to promote the progression of chordoma.
    Wen L; Xie B; Li H; Huang J; Shi Y; Tao Y; Chen Y
    Neurosurg Focus; 2024 May; 56(5):E17. PubMed ID: 38691868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.